Anavex Life Sciences Corp (AVXL)

[falconer66a]

Good scrutiny and understanding of Anavex science.

I have followed closely company developments most every step of the way in the last 6 years--all of which have been very very positive with zero negatives--another example-Dr.Randi Hagerman--Of Fragile X foundation and Univ.of California hospital--who had very positive comments on 2-73 after participating in the Rett Syndrome trial. Falconer your scientific contributions here just add reasons as to why I am invested here--much appreciated !!!

Thank you.

But your analysis of the science supporting the Anavex molecules has been right-on, from the start. It’s this. Simply, over the years lots of info on the Anavex molecules treating various (mostly CNS diseases) in both murines (lab rodents) and humans has appeared. Anyone with any curiosity would ask some questions about these results; particularly with any knowledge, scientific (me) or general (you), about new drugs in general.

Yes, you, too, looked for side effects information, and questionable therapeutic outcomes (such as those of the other Alzheimer’s drug, Aduhelm). You searched and considered the information on Anavex 2-73, and you didn’t find much (well, anything) that was negative.

Actually, a few years ago, there were two things negative about the science of blarcamesine. First, it simply hadn’t yet been tested for any length or size in real humans. Clinical tests in humans were preliminary, tiny, and even uncontrolled (no placebo arms). Therefore, the early accounts of efficacy were legitimately suspect. Big trials were needed; today, they are ongoing and will come to conclusion shortly.

The other really big question was how blarcamesine, as a single small molecule might be able to prompt such a wide diversity of efficacious results; AND, do it so safely. Simply, there was no biochemical explanation. The molecular specifics of the drug’s mechanisms of action (MOAs) were a mystery. Especially when working in the CNS. You don’t have to have scientific training to know that drugs acting in the CNS almost universally have considerable side effects. Blarcamesine had virtually none.

But, now, there have been larger human trials. Not a one has produced either therapeutic failures, or negating adverse events. Simply, every strand of evidence shows that the drug works, safely.

Finally, it is now more fully understood how this happens, what the biochemical mechanisms of action of the drug are: propitious activation of the sigma-1 receptor protein, which consequently modulates and promotes a diversity of favorable downstream cell-keeping processes, resulting in cell health (for a diversity of diseases).

All of us will continue to search for negating results and evidence that would poke sinking holes in the ever more detailed Anavex science story. You were correct. You found none at the beginning, and no such evidence of inefficacy or safety hazard has appeared. Well done.